Patient Name : Mr.

SHADAB KHAN Registered : 28/07/2026 11:32AM

Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 03:20PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: EDTA

COMPLETE BLOOD COUNT*

Haemoglobin 14.5 gm/dL 13-17
(Method:SLS Hb method)
Erythrocytes Count (RBC Count) 5.17 million per 4.5-5.9
(Method: Hydrodynamic focussing) c.u. mm.
Hematocrit (HCT/PCV) 42.8 % 40-52
(Method:RBC Pulse Height Detection)
Blood Cell Indices (RBC)
(Method: Calculated)

M.C.V. L 82.8 femtolitres 83 - 101

M.C.H. 28.0 pico-grams 27-32
M.C.H.C. 33.9 g/dL 31.5 - 34.5
RBC Distribution Width -CV (RDW-CV) 14.0 % 11 - 16
Total W.B.C. Count 9,060 cells/[Link]. 5000 - 10000
(Method: Flow Cytometry)
W.B.C. Differential Count
(Method: Flowcytometry)

Neutrophils 58 % 50 - 62
Lymphocytes 31 % 25 - 40
Eosinophils 03 % 1-6
Monocytes H 08 % 3-7
W.B.C. Absolute Values
(Method: Calculated)

Absolute Neutrophils Count(ANC) 5.2 10^3/ul 2-7

Absolute Lymphocytes Count(ALC) 2.8 10^3/ul 1-3
Absolute Eosinophils Count(AEC) 0.3 10^3/ul 0.1 - 0.5
Absolute Monocytes Count(AMC) 0.7 10^3/ul 0.2 - 1.0
Platelet Counts
Platelet Count 2,27,000 /cmm 150000 - 400000

Page 1 of 12
Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 03:20PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

(Method:Hydrodynamic Focussing)
Peripheral Smear Findings
Abnormalities of Erythrocytes Normocytic & normochromic
Abnormalities of Leucocytes No Immature Leucocytes
Platelets on Smear Adequate

Page 2 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:05PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Serum

Mini Lipid
Serum Cholesterol 173 mg/dL Upto 200
(Method:Enzymatic CHOD-PAP )
(Desirable <200 mg/dl;Borderline
High 200-239 mg/dl;High ≥ 240mg/dl)
Serum Triglyceride 102 mg/dL Upto 150
(Method Enzymatic Colorimitric )
(Normal <150 mg/dl;Borderline High 150-199 mg/dl;
High 200- 499 mg/dl;Very High ≥ 500 mg/dl)
Serum High Density Lipoproteins 40.7 mg/dL 35-55
Cholesterol (HDL-C)
(Method Direct Homogeneous Enzymatic)
(Men:No Risk >55 mg/dl
Moderate risk 35-55 mg/dl,high risk <35 mg/dl
Women: No Risk >65 mg/dl
Moderate risk 45-65,high risk <45 mg/dl)
Serum Low Density Lipoproteins 111.9 mg/dL Upto 100
Cholesterol (LDL-C)
(Method:Homogeneous Enzymatic)
(Optimal <100 mg/dl;Near
optimal/above optimal 100-129
Borderline High 130-159 mg/dl
High 160-189 mg/dl;Very high ≥ 190 mg/dl)
Serum Very Low Density Lipoproteins 20 mg/dL 10-30
Cholesterol (VLDL-C)
(Method : Calculated)
Total Cholesterol/Serum High Density 4.25 Ratio Less 4.5
Lipoproteins Cholesterol(TC/HDL-C)
(Method : Calculated)
Low Density Lipoprotiens/High Density 2.75 Ratio Less 3.0
Lipoprotiens Cholestrol Ratio
(Method : Calculated)

Page 3 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:05PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Serum

Serum Bilirubin
Total Serum Bilirubin 0.66 mg/dl 0.1-1.0
(Method: Diazonium Ion )
.

Direct Serum Bilirubin 0.12 mg/dL 0.02-0.25

(Method: Diazotized Sulfanilic Acid)
.

Indirect Serum Bilirubin 0.54 mg/dL 0.08-0.75

(Method: Calculated)
.

Primary Sample Type: Serum

Serum Creatinine
Serum Creatinine 0.90 mg/dL 0.6 - 1.4
(Method: Jaffé Kinetic)
(The Normal relationship between body Weight and Serum creatinine:
*LESS THAN 50KG : 0.6 to 1.0 mg/dl,*Between 55 to 80kg : 0.8 to 1.2 mg/dl,*More than 80kg : 1.0 to 1.4 mg/dl)
Estimated Glomerular Filtration 98.5
Rate(eGFR)
Calculation-MDRD
Refrence Range : *eGFR less than 60 mL/min/1.73m^2 for 3 months is indicative of chronic Kidney Disease(CKD)*eGFR
less than 15 mL/min/1.7m^2 is indicative of Renal failure.
Primary Sample Type: Serum

Serum Sodium
Serum Sodium L 133 mEq/L 136-145
(Method: Ion Selective Electrode)
Primary Sample Type: Serum

Serum Potassium
Serum Potassium 4.9 mEq/L 3.50 - 5.00
(Method: Ion Selective Electrode)
Primary Sample Type: Serum

Serum S.G.P.T.
Serum Glutamic Pyruvate H 55 U/L 0-50
Transaminase(S.G.P.T.)

Page 4 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:05PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Serum

Serum S.G.O.T.
Serum Aspartate Amino 27 U/L 10-35
Transferase(AST/SGOT)
(Method: UV without P5P)
Primary Sample Type: Serum

Serum Urea
Serum Urea 33 mg/dL 20 - 40
(Method:Urease-GLDH)
Primary Sample Type: Serum

Serum Uric Acid

Serum Uric Acid 5.70 mg /dl 3.4 - 7
(Method: Uricase-PAP)

Page 5 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 03:31PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Serum

THYROID PROFILE
Thyroid Stimulating Hormone (TSH 3rd 3.36 uIU/mL 0.27 - 4.2
generation assay)
(Electrochemiluminescence Immuno Assay ECLIA)
.
Total Serum Tri-iodothyronine (T3) Assay 2.37 nmol/L 1.2 - 3.1
(Method:ECLIA)
.
Total Serum Thyroxine (T4) Assay 135 66 - 181
(Method:ECLIA)

Page 6 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 06:17PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Urine

URINE ROUTINE
Physical Examination
Urine Colour Pale Yellow Pale-Yellow
Reaction Acidic Acidic/Alkaline
Specific Gravity 1.025 1.010 - 1.025
Chemical Examination
Albumin Nil Traces/Nil
Glucose Nil Absent
Ketone Absent Absent
Bilirubin Absent Absent
Urobilinogen Absent Absent
Nitrite Absent Absent
Microscopic Examination
Pus Cells (WBC) 1.10 hpf 0.0-5.0
Red Blood Cells(RBC) 2.50 hpf 0.0-4.0
Squamous Epithelial cell 0.00 hpf 0.0-6.0
Non-Squamous Epithelial cell 0.30 hpf 0-1
Casts 0.00 hpf 0.0-3.0
Hyaline Cast 0.00 hpf 0.0-3.0
Pathological Cast 0.00 hpf 0.0-3.0
Bacteria 4.0 0.0-310.0
Crystals Calcium hpf 0.0-30.0
Oxalate (10.2)
Yeast like cells 0.00 hpf 0.0-2.0

Page 7 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 06:17PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Note:-
Leukocytes
False-positive influence
• Cefoxitin, curcumin, levodopa, N-acetyl cysteine, acid or tetracycline and captopril
• Lowered specific gravity
False-negative influence
• False-negative results can occur during treatment with captopril. The test pad is not affected by the ingestion of ascorbic acid (up to 750 mg/dL)
Nitrite
False-positive influence
• Phenazopyridine from 300 mg/L False-negative influence
• Medications with 2-mercaptoethanesulphonate-sodium (MESNA) and sulfonamide (trimethoprim, but only in extremely high concentrations (1080 mg/L))
The test pad is not affected by the ingestion of ascorbic acid (up to 3,000 mg/dL).
Protein
False-positive influence
• During therapy with p-aminosalicylic acid, chloroquine, quinidine or nitrofurantoin The test pad is not affected by the ingestion of ascorbic acid (up to
4,000 mg/dL).
Glucose
False-positive influence
• Medication with 2-mercaptoethanesulphonate-sodium (MESNA) False-negative [Link] with nitrofurantoin may produce false-negative readings The
test pad is not affected by the ingestion of ascorbic acid (up to 750 mg/dL).
Ketones
False-positive influence
• Captopril, curcumin, imipenem and 2-mercaptoethanesulphonate-sodium (MESNA) or other sulfhydryl-containing compounds • Formaldehyde (stabilizer) may cause
falsepositive readings, but only in extremely high concentrations
The test pad is not affected by the ingestion of ascorbic acid (up to 4,000 mg/dL).
Urobilinogen
False-positive influence
• Urine from patients who are being treated with p-aminosalicyclic acid or sulfamethoxazol and phenazopyridine may show a false-positive reaction
• Urines with high pH values (pH > 9) False-negative influence
• Treatments with levodopa, cefoxitin and sulhydril-containing compounds (n-acetylcysteine) cause false-negative results the test pad is not affected by the
ingestion of ascorbic acid (up to 4,000 mg/dL).
Bilirubin False-positive influence
• False-positive readings are obtained during treatments with imipenem, penicillin and p-aminosalicyclic acid or due to contamination of urine container with
hydrochloric acid
• Highly basic urines (pH > 9) • Large amounts of urobilinogen in the urine affect the color change of the bilirubin test and also lead to false-positive
results False-negative influence
• Treatments with 2-mercaptoethanesulphonate-sodium (MESNA) the test pad is not affected by the ingestion of ascorbic acid (up to 400 mg/dL).
Blood (erythrocytes/hemoglobin)
False-positive influence
• Patients with phenazopyridine medications
• High counts of leukocytes (500 LEU/μL), highly basic urines (pH > 9) and low specific gravity (< 1,005) may show false-positive test results
• Medications with 2-mercaptoethanesulphonate-sodium (MESNA) can lead to falsepositive or false negative reading of reagent pad color changes False-negative
influence
• When formalin is used to preserve the urine with nitrofurantoin and quinidines, falsenegative results are obtained
The test pad is not affected by the ingestion of ascorbic acid (up to 1,000 mg/dl)

Page 8 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 08:11PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Fluoride

Fasting Plasma Glucose(Venous)

Fasting Plasma glucose (Venous) H 121 mg /dl 70 - 100
(Method: Hexokinase)
(Reference Ranges 70 to 100 mg/dl;
Impaired Sugar 100 to 126 mg/dl;
Diabetes mellitus >126 mg/dl)
Primary Sample Type: Fluoride

PP Plasma Glucose (2 hr)

Plasma Glucose 2 Hours after meals H 196 mg /dL 100-140
(Venous)
(Method: Hexokinase)
(Reference Ranges <140 mg/dl;
Impaired Sugar 140 to 200 mg/dl;
Diabetes mellitus >200 mg/dl)

Page 9 of 12
 Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:04PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Primary Sample Type: Whole Blood EDTA

GLYCO HB (HbA1c) HPLC

GLYCOSYLATED HAEMOGLOBIN (Hb-A1c) -- 6.9 %
NGSP Unit
(Ion-Exchange High-Performance Liquid
Chromatography)
INTERPRETATION :

The following ranges may be used for interpretation of results. However, factors such as duration of diabetes,
adherence to therapy and the age of the patient should also be considered in assessing the degree of blood
glucose control.
Haemoglobin A1C (%) Degree of Glucose Control mmol/mol
NGSP Unit IFCC Unit
> 8 Action Suggested* >63.9
7-8 Fair Control 53.0 -63.9
< 7 Goal** <63.9
6-7 Near-normal glycemia 42.1 -63.9
<5.7% Non-diabetic level <39
*High risk of developing long term complications such as Retinopathy, Nephropathy, Neuropathy, Cardiopathy, etc.
**Some danger of hypoglycemic reaction in Type 1diabetics. Some glucose intolerant individuals and "subclinical"
diabetics may demonstrate HbA1C levels in this area.

N.B. : Test carried out on Automated D10 Bio Rad HPLC Analyser.
Clinical Implications:
*Values are frequently increased in persons with poorly controlled or newly diagnosed diabetes.
*With optimal control, the HbA 1c moves toward normal levels.
*A diabetic patient who recently comes under good control may still show higher concentrations of glycosylated
hemoglobin. This level declines gradually over several months as nearly normal glycosylated *Increases in
glycosylated hemoglobin occur in the following non-diabetic conditions: a. Iron-deficiency anemia b. Splenectomy
c. Alcohol toxicity d. Lead toxicity
*Decreases in A 1c occur in the following non-diabetic conditions: a. Hemolytic anemia b. chronic blood loss
*Pregnancy d. chronic renal failure.
Interfering Factors:
*Presence of Hb F and H causes falsely elevated values. 2. Presence of Hb S, C, E, D, G, and Lepore (autosomal
recessive mutation resulting in a hemoglobinopathy) causes falsely decreased values.

Page 10 of 12
Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:04PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Glycosylated Haemoglobin --- (HbA1c)- 51.92 mmol/mol

IFCC unit
(Ion-Exchange High-Performance Liquid
Chromatography)
INTERPRETATION :
The following ranges may be used for interpretation of results. However, factors such as duration of diabetes,
adherence to therapy and the age of the patient should also be considered in assessing the degree of blood
glucose control.
Haemoglobin A1C (%)NGSP mmol/IFCC Unit Degree of Glucose Control Unit
> 8 >63.9 Action Suggested*
7-8 53.0 -63.9 Fair Control
< 7 <63.9 Goal**
6-7 42.1 -63.9 Near-normal glycemia
< 6% <42.1 Non-diabetic level
*High risk of developing long term complications such as Retinopathy, Nephropathy, Neuropathy, Cardiopathy, etc.
**Some danger of hypoglycemic reaction in Type 1diabetics. Some glucose intolerant individuals and "subclinical"
diabetics may demonstrate HbA1C levels in this area.
N.B. : Test carried out on Automated D10 Bio Rad HPLC Analyser.
Clinical Implications:
* Values are frequently increased in persons with poorly controlled or newly diagnosed diabetes.
* With optimal control, the HbA 1c moves toward normal levels.
* A diabetic patient who recently comes under good control may still show higher concentrations of glycosylated
hemoglobin. This level declines gradually over several months as nearly normal glycosylated hemoglobin replaces
older RBCs with higher concentrations.
* Increases in glycosylated hemoglobin occur in the following non-diabetic conditions: a. Iron-deficiency anemia
b. Splenectomy c. Alcohol toxicity d. Lead toxicity
* Decreases in A 1c occur in the following non-diabetic conditions: a. Hemolytic anemia b. chronic blood loss c.
Pregnancy d. chronic renal failure.
Interfering Factors:
* Presence of Hb F and H causes falsely elevated values. 2. Presence of Hb S, C, E, D, G, and Lepore (autosomal
recessive mutation resulting in a hemoglobinopathy) causes falsely decreased values.

Page 11 of 12
Patient Name : Mr. SHADAB KHAN Registered : 28/07/2026 11:32AM
Referring Doctor : Self SampleCollection : 28/07/2026 11:35AM
Age/Sex : 42 YEARS/MALE Reported : 28/07/2026 04:04PM
Lab No. : 092607280010 Sample No : 11468575

TEST NAME RESULTS UNITS [Link]

Estimated Average Glucose (eAG) 151.33 mg/dl

(Ion-Exchange High-Performance Liquid
Chromatography)
NOTE:
* eAG is directly related to A1c.
* An A1c of 7%-the goal for most people with diabetes-is the equivalent of an eAG of 154 mg/dl.
* eAG may help facilitate a better understanding of actual daily control helping you and your
health care provider to make necessary changes to your diet and physical activity to improve
overall diabetes management.

INTERPRETATION : The following ranges may be used for interpretation of results. However, factors
such as duration of diabetes, adherence to therapy and the age of the patient should also be
considered in assessing the degree of blood glucose control.

eAG (mg/dl) Degree of Glucose Control

_____________ ___________________________

>183 Action Suggested*

154-183 Fair Control

<154 Goal**

126-154 Near-normal glycemia

<126 Non-diabetic level

* High risk of developing long term complications such as etinopathy, Nephropathy, Neuropathy,
Cardiopathy, etc.
** Some danger of hypoglycemic reaction in Type 1diabetics. Some glucose intolerant individuals
and "subclinical" diabetics may demonstrate HbA1C levels in this area.

*** End Of Report ***

Page 12 of 12